A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

April 27, 2027

Study Completion Date

April 27, 2027

Conditions
Chronic Kidney Disease
Interventions
DRUG

Dapagliflozin

Dapagliflozin by oral administration

Trial Locations (37)

100034

RECRUITING

Research Site, Beijing

100044

RECRUITING

Research Site, Beijing

100068

RECRUITING

Research Site, Beijing

100191

RECRUITING

Research Site, Beijing

102206

RECRUITING

Research Site, Beijing

130021

RECRUITING

Research Site, Changchun

132011

RECRUITING

Research Site, Jilin

150000

RECRUITING

Research Site, Harbin

200090

RECRUITING

Research Site, Shanghai

210029

RECRUITING

Research Site, Nanjing

214023

RECRUITING

Research Site, Wuxi

215004

RECRUITING

Research Site, Suzhou

223399

RECRUITING

Research Site, Huaian

230601

RECRUITING

Research Site, Hefei

236012

RECRUITING

Research Site, Fuyang

236600

RECRUITING

Research Site, Fuyang

241000

RECRUITING

Research Site, Wuhu

250014

RECRUITING

Research Site, Jinan

271099

RECRUITING

Research Site, Taian

272029

RECRUITING

Research Site, Jining

276199

RECRUITING

Research Site, Linyi

300121

RECRUITING

Research Site, Tianjin

315010

RECRUITING

Research Site, Ningbo

330006

RECRUITING

Research Site, Nanchang

341099

RECRUITING

Research Site, Ganzhou

350001

TERMINATED

Research Site, Fuzhou

361004

RECRUITING

Research Site, Xiamen

410011

WITHDRAWN

Research Site, Changsha

421001

RECRUITING

Research Site, Hengyang

463000

NOT_YET_RECRUITING

Research Site, Zhumadian

516001

RECRUITING

Research Site, Huizhou

518036

RECRUITING

Research Site, Shenzhen

523059

RECRUITING

Research Site, Dongguan

528308

RECRUITING

Research Site, Foshan

530021

RECRUITING

Research Site, Nanning

710000

RECRUITING

Research Site, Xi'an

730000

RECRUITING

Research Site, Lanzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY